1
|
Fieux M, Lisan Q, Nevoux J, Bartier S, Darnal E, Mahieu A, Karam P, Alexandru M, Papon JF. French health insurance data for chronic rhinosinusitis with nasal polyps between 2011 and 2018: A STROBE-compliant analysis. Eur Ann Otorhinolaryngol Head Neck Dis 2023; 140:65-69. [PMID: 36028425 DOI: 10.1016/j.anorl.2022.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
AIMS The main aim of the present study was to report the annual volume of surgeries performed for chronic rhinosinusitis with nasal polyps (CRSwNP) in France, based on health insurance data. The secondary objectives were to describe the different characteristics of the surgeries and their complications, and to estimate the number of patients eligible for biotherapy. MATERIAL AND METHODS This was a descriptive observational retrospective study using data from French national health insurance databases for the period 2011-2018. Inclusion criteria comprised all hospital stays with procedures related to CRSwNP according to the French Common Classification of Medical Acts and consistent with French practices. RESULTS Ninety-two thousand one hundred and fourty one patients (92,141) for 92,884 admissions for CRSwNP surgery were analyzed, providing an accurate representation of CRSwNP surgery in France between 2011 and 2018. The revision surgery rate for patients operated on in 2011 was 13.0% (1,457/11,212), corresponding to an average annual rate of 1.86% over 7 years. In the 11,750 sinus surgery admissions in 2018, the complications rate was only 0.65% (77/11,750). CONCLUSION Sinus surgery is safe (0.65% complications) and reliable (estimated revision rate, 5.5%: 5,078/92,884). This study provides the first evaluation of the target population for biotherapy in France.
Collapse
Affiliation(s)
- M Fieux
- Université de Lyon, université Lyon 1, hospices civils de Lyon, centre hospitalier Lyon Sud, service d'ORL, d'otoneurochirurgie et de chirurgie cervico-faciale, 69495 Pierre-Bénite cedex, France; Institut Mondor de recherche biomédicale Inserm-UPEC UMR 955, CNRS EMR 7000, 94010 Créteil, France.
| | - Q Lisan
- Inserm UMR 970, department of epidemiology, 75015 Paris, France; Service d'ORL et chirurgie cervico-faciale, Foch Hospital, 92150 Suresnes, France; École de Médecine, Université Versailles Saint-Quentin-en-Yvelines (Paris Saclay University), 92150 Suresnes, France
| | - J Nevoux
- Université Paris-Saclay, AP-HP, hôpital Bicêtre, service d'ORL et de chirurgie cervico-faciale, DMU Neuroscience, Le Kremlin-Bicêtre, France; Institut Mondor de recherche biomédicale Inserm-UPEC UMR 955, CNRS ERL7000, 94275 Créteil, France
| | - S Bartier
- Service d'ORL, de chirurgie cervico faciale, hôpital Henri-Mondor, assistance Publique des hôpitaux de Paris, Créteil, France; Institut Mondor de recherche biomédicale Inserm-UPEC UMR 955, CNRS EMR 7000, 94010 Créteil, France
| | - E Darnal
- Sanofi-Aventis France, 94250 Gentilly, France
| | - A Mahieu
- Sanofi-Aventis France, 94250 Gentilly, France
| | - P Karam
- Pierre Karam Conseil Santé, 69310 Ecully, France
| | - M Alexandru
- Université Paris-Saclay, AP-HP, hôpital Bicêtre, service d'ORL et de chirurgie cervico-faciale, DMU Neuroscience, Le Kremlin-Bicêtre, France; Institut Mondor de recherche biomédicale Inserm-UPEC UMR 955, CNRS ERL7000, 94275 Créteil, France
| | - J F Papon
- Université Paris-Saclay, AP-HP, hôpital Bicêtre, service d'ORL et de chirurgie cervico-faciale, DMU Neuroscience, Le Kremlin-Bicêtre, France; Institut Mondor de recherche biomédicale Inserm-UPEC UMR 955, CNRS ERL7000, 94275 Créteil, France
| |
Collapse
|